Deep search
Search
Copilot
Images
Videos
Maps
News
Shopping
More
Flights
Travel
Hotels
Notebook
Top stories
Sports
U.S.
Local
World
Science
Technology
Entertainment
Business
More
Politics
Any time
Past hour
Past 24 hours
Past 7 days
Past 30 days
Best match
Most recent
Moderna stock drops
Moderna’s stock is falling. Goldman Sachs says it’s no longer a buy.
Shares of vaccine maker Moderna fell Wednesday as Goldman Sachs lowered its rating after the biotech’s second cut to product revenue guidance in six months.
Moderna downgraded to Neutral from Buy at Goldman Sachs
Goldman Sachs downgraded Moderna (MRNA) to Neutral from Buy with a price target of $51, down from $99. The recent product revenue guidance
Moderna stock drops as Goldman Sachs cuts rating
Moderna (NASDAQ:MRNA) shares about 3% ahead of Wednesday market open after Goldman Sachs (NYSE:GS) cut its rating on the stock to Neutral from Buy.
Moderna down as Goldman Sachs downgrades on revenue outlook
Moderna (NASDAQ:MRNA) traded lower in the premarket on Wednesday after Goldman Sachs downgraded the COVID-19 vaccine maker to Neutral from Buy, citing a lack of clarity over its revenue outlook. Goldman's downgrade comes days after the Cambridge,
8d
on MSN
Moderna Stock Jumps as Biotech Gets $590M From US To Develop Bird-Flu Vaccine
Key Takeaways Moderna received a $590 million award from the U.S. government to speed development of a vaccine that could be ...
4d
on MSN
3 Things You Need to Know if You Buy Moderna Today
In that vein, let's learn about the three most important things you should know if you're going to consider investing in ...
2d
Former vaccines minister Nadhim Zahawi at Covid inquiry
Representatives of Moderna Biotech UK and NHS England will also be questioned by the inquiry, led by crossbench peer Baroness ...
20h
From Underperformance To Opportunity: Biotech's Case For 2025
Despite continued underperformance in 2024, the biotech sector enters 2025 with a brighter outlook driven by groundbreaking ...
13d
Is Moderna a Bad-News Buy for 2025?
Moderna (NASDAQ: MRNA) was one of the hottest companies of early pandemic times, delivering a coronavirus vaccine to market ...
FiercePharma
2d
Moderna, Novo Nordisk slammed for breaching UK drug marketing code yet again
Moderna and Novo Nordisk are once again in the bad books of the U.K.’s drug marketing watchdog. | Moderna and Novo Nordisk ...
8d
Where Will Moderna Be in 3 Years?
Before beginning the discussion of where this company is going, let's set expectations appropriately. Moderna won't be ...
FierceBiotech
8d
HHS gives Moderna $590M to 'accelerate' bird flu vaccine trials
The government wants Moderna to push forward with various bird flu vaccines as well as mRNA shots for other influenza strains ...
2d
on MSN
Watch live: Kemi Badenoch gives evidence at UK Covid inquiry
Watch live as Kemi Badenoch gives evidence to the UK Covid inquiry on Wednesday, 27 January. The inquiry will also hear from ...
13d
on MSN
Down 79%, Is Moderna Stock a Bad-News Buy on the Dip?
Moderna (NASDAQ: MRNA) shareholders have been having a rough time lately. The biotech stock rocketed higher last spring, but ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback